AbCellera Biologics Inc. (ABCL): Capital Expenditures
$42.77M
Year ended 2025-12-31
$24.73M
Trailing 12 months to 2026-06-30
-15.4%
3-year compound annual growth
+34.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.77M | -45.4% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $78.40M | +1.9% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $76.95M | +8.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $70.66M | +20.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $58.45M | +504.3% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $9.67M | +142.0% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $4.00M | n/a | 2022-02-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $2.35M | +90.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $66.0K | +135.7% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $495.0K | -3.1% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $333.0K | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
Compare ABCL, CTMX, BCYC, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗